This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 02:20, 7 August 2011 (Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[Misplaced Pages:WikiProject Chemicals/Chembox validation|Chem/Drugbo). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 02:20, 7 August 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[Misplaced Pages:WikiProject Chemicals/Chembox validation|Chem/Drugbo)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff){{drugbox | Verifiedfields = changed | UNII_Ref = | UNII = N673F6W2VH | verifiedrevid = 407876319 | IUPAC_name = N-(1-cyanocyclopropyl)-4-fluoro-N-{(1S)-2,2,2-trifluoro-1-ethyl}-L-leucinamide | synonyms = (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-{-4-yl}ethyl]amino}pentanamide | image = Odanacatib Structural Formulae V.1.svg | CAS_number = 603139-19-1 | CAS_supplemental = | ATC_prefix = none | ATC_suffix = | ATC_supplemental = | PubChem = 10152654 | DrugBank_Ref = | DrugBank = | chemical_formula = | C=25 | H=27 | F=4 | N=3 | O=3 | S=1 | molecular_weight = 525.56 g/mol | smiles = CC(C)(CC(C(=O)NC1(CC1)C#N)NC(C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = oral }} Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption.
It is being developed by Merck & Co. As of November 2009, Merck is conducting phase III clinical trials.
References
- PMID 18685424
- Gauthier JY, Chauret N, Cromlish W; et al. (2008). "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K". Bioorg. Med. Chem. Lett. 18 (3): 923–8. doi:10.1016/j.bmcl.2007.12.047. PMID 18226527.
{{cite journal}}
: Explicit use of et al. in:|author=
(help); Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link)
Drugs for treatment of bone diseases (M05) | |
---|---|
Bisphosphonates | |
Bone morphogenetic proteins | |
Other |
|
This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it. |